Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL3255863 | 0.84 | TSHR (0.54) | TSHRSMN1; SMN2MAPTALDH1A1KMT2A | |
| Benzene SCHEMBL27324158 | 0.84 | TSHR (0.43) | TSHRMAPTLMNAALDH1A1KMT2A | |
| Toluene SCHEMBL28241304 | 0.83 | LMNA (0.52) | TSHRSMN1; SMN2MAPTLMNAALDH1A1 | |
| Aniline SCHEMBL27761830 | 0.83 | TSHR (0.52) | TSHRSMN1; SMN2MAPTLMNAALDH1A1 | |
| Phenol SCHEMBL27975587 | 0.83 | CA12 (0.52) | TSHRMAPTLMNAALDH1A1KMT2A | |
| Biphenyl SCHEMBL27819830 | 0.82 | SMN1; SMN2 (0.56) | TSHRSMN1; SMN2MAPTKDM4EALDH1A1 | |
| Biphenyl SCHEMBL5494233 | 0.82 | MAPT (0.52) | TSHRSMN1; SMN2MAPTLMNAKDM4E | |
| Biphenyl SCHEMBL27492413 | 0.82 | TSHR (0.52) | TSHRSMN1; SMN2MAPTTAAR1KDM4E | |
| Biphenyl SCHEMBL10565823 | 0.82 | LMNA (0.48) | TSHRSMN1; SMN2MAPTLMNATAAR1 | |
| Biphenyl SCHEMBL27677322 | 0.82 | TSHR (0.52) | TSHRSMN1; SMN2MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100591662-C | Process and intermediates for the preparation of 3- (amino) -3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof | SCHERING CORP | 2010-02-24 | — | — | CN | claimed |
| CN-1805932-A | Processes and intermediates for the preparation of (1R, 2S, 5S) -3-azabicyclo [ 3, 1, 0 ] hexane-2-carboxamide, N- [ 3-amino-1- (cyclobutylmethyl) -2, 3-dioxopropyl ] -3- [ (2S) -2- [ [ [ 1, 1-dimethylethyl ] amino ] carbonylamino ] -3, 3-dimethyl-1-oxobutyl ] -6, 6-dimethyl | SCHERING CORP (US) | 2006-07-19 | — | — | CN | claimed |
| CN-1805920-A | Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof | SCHERING CORP (US) | 2006-07-19 | — | — | CN | claimed |
| CN-118055926-A | ROCK2 inhibitors and uses thereof | 哈佛大学的校长及成员们 | 2024-05-17 | — | — | CN | disclosed |
| CN-117965536-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117512080-A | Multiplexing using microparticles in dispensing | 生物-拉德实验室公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117529340-A | Improved compositions for delivery of mRNA | 翻译生物公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230406877-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2023-12-21 | — | — | US | disclosed |
| CN-117136182-A | Cationic lipids based on \"God\" buffers | 翻译生物公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| CN-1805932-A | Processes and intermediates for the preparation of (1R, 2S, 5S) -3-azabicyclo [ 3, 1, 0 ] hexane-2-carboxamide, N- [ 3-amino-1- (cyclobutylmethyl) -2, 3-dioxopropyl ] -3- [ (2S) -2- [ [ [ 1, 1-dimethylethyl ] amino ] carbonylamino ] -3, 3-dimethyl-1-oxobutyl ] -6, 6-dimethyl | SCHERING CORP (US) | 2006-07-19 | — | — | CN | disclosed |
| US-20060149047-A1 | N-CARBOBENZYLOXY (N-CBZ)-DEPROTECTING ENZYME AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-06 | — | — | US | disclosed |
| EP-1629087-A2 | N-CARBOBENZYLOXY (N-CBZ)-DEPROTECTING ENZYME AND USES THEREFOR | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| CN-1662496-A | Cannabinoid receptor agonists | SCHERING CORP (US) | 2005-08-31 | — | — | CN | disclosed |
| WO-2005001047-A2 | N-CARBOBENZYLOXY (N-CBZ)-DEPROTECTING ENZYME AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
| US-6828119-B2 | Deprotecting a hydroxide or amine; obtain sample, incubate with enzyme, remoe protecting group, recover amine | BRISTOL MYERS SQUIBB COMPANY | 2004-12-07 | — | — | US | disclosed |
| EP-1348025-A2 | ENZYMATIC DEPROTECTION OF AMINES AND HYDROXIDES | Bristol-Myers Squibb Company (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20020123110-A1 | Enzymatic deprotection of amines and hydroxides | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-05 | — | — | US | disclosed |
| WO-2002053724-A2 | ENZYMATIC DEPROTECTION OF AMINES AND HYDROXIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | TSHR 1282/4885SMN1; SMN2 242/4885MAPT 1303/4885 |
| US-20230406877-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | TSHR 82/4885SMN1; SMN2 2658/4885MAPT 3786/4885 |
| US-20060149047-A1 | N-CARBOBENZYLOXY (N-CBZ)-DEPROTECTING ENZYME AND USES THEREFOR | CMBL, BCHE, NOTUM | TSHR 3520/4885SMN1; SMN2 2567/4885MAPT 3352/4885 |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | TSHR 82/4885SMN1; SMN2 2658/4885MAPT 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.